Intent to Sole Source - Biolegend Oliogos NOI-CC-OLAO-26-004813
Summary
AI-generated · Apr 30, 2026Custom oligos are required by the PACT team at the Clinical Center to enable single-cell copy-number analysis with the Tapestri instrument for CAR-T cell products, to support clinical QC assays. The NIH intends to negotiate a sole-source contract with Biolegend, based on the assertion that only one source can satisfy the requirement (41 U.S.C. 253(c)(1); FAR 6.302-1).
This is not a request for proposals. Other capable vendors may submit a capability statement by email for consideration.
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Biolegend. Acquisition Description: Custom Oligios needed by PACT team at CCE to do single cell copy number analysis with Tapestri instrument for CAR-T cell products to support clinical QC assay. The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-26-004813) by 12:00 PM eastern standard time on 05/08/2026 to: valerie.gregorio@nih.gov. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
From Special Notice posted on Apr 29, 2026Notice history
1-
Special Notice LATEST Posted Apr 29, 2026
Details
Award Information
Not yet awarded
Agency
Place of Performance
USA